These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 23147077

  • 1. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
    Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y, Okada K, Inoue Y, Yamamoto Y, Nakagawa H, Yao S, Kawamoto T, Uchikawa O.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7326-9. PubMed ID: 23147077
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of WO2012003387, Gilead's ASK1 inhibitors.
    Norman P.
    Expert Opin Ther Pat; 2012 Apr 15; 22(4):455-9. PubMed ID: 22439661
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.
    Monastyrskyi A, Bayle S, Quereda V, Grant W, Cameron M, Duckett D, Roush W.
    Bioorg Med Chem Lett; 2018 Feb 01; 28(3):400-404. PubMed ID: 29277458
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
    Oguro Y, Cary DR, Miyamoto N, Tawada M, Iwata H, Miki H, Hori A, Imamura S.
    Bioorg Med Chem; 2013 Aug 01; 21(15):4714-29. PubMed ID: 23755884
    [Abstract] [Full Text] [Related]

  • 5. Rational design of apoptosis signal-regulating kinase 1 inhibitors: discovering novel structural scaffold.
    Volynets GP, Bdzhola VG, Golub AG, Synyugin AR, Chekanov MA, Kukharenko OP, Yarmoluk SM.
    Eur J Med Chem; 2013 Mar 01; 61():104-15. PubMed ID: 23041041
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
    Ducray R, Simpson I, Jung FH, Nissink JW, Kenny PW, Fitzek M, Walker GE, Ward LT, Hudson K.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4698-701. PubMed ID: 21775140
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Parker P, Workman P, Waterfield MD.
    Bioorg Med Chem; 2007 Sep 01; 15(17):5837-44. PubMed ID: 17601739
    [Abstract] [Full Text] [Related]

  • 8. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines.
    Buckley GM, Fosbeary R, Fraser JL, Gowers L, Higueruelo AP, James LA, Jenkins K, Mack SR, Morgan T, Parry DM, Pitt WR, Rausch O, Richard MD, Sabin V.
    Bioorg Med Chem Lett; 2008 Jun 15; 18(12):3656-60. PubMed ID: 18501603
    [Abstract] [Full Text] [Related]

  • 9. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S, Miyamoto N, Hirayama T, Oki H, Okada K, Tawada M, Iwata H, Nakamura K, Yamasaki S, Miki H, Hori A, Imamura S.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7686-98. PubMed ID: 24216091
    [Abstract] [Full Text] [Related]

  • 10. ASK1 pharmacophore model derived from diverse classes of inhibitors.
    Starosyla SA, Volynets GP, Bdzhola VG, Golub AG, Protopopov MV, Yarmoluk SM.
    Bioorg Med Chem Lett; 2014 Sep 15; 24(18):4418-4423. PubMed ID: 25172422
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors.
    Hayakawa M, Kaizawa H, Kawaguchi K, Ishikawa N, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto S, Raynaud FI, Waterfield MD, Parker P, Workman P.
    Bioorg Med Chem; 2007 Jan 01; 15(1):403-12. PubMed ID: 17049248
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.
    Hou S, Yang X, Yang Y, Tong Y, Chen Q, Wan B, Wei R, Lu T, Chen Y, Hu Q.
    Eur J Med Chem; 2021 Aug 05; 220():113482. PubMed ID: 33906048
    [Abstract] [Full Text] [Related]

  • 13. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C, Duffey MO, Gould AE, Kulkarni B, Liu JX, Menon S, Nagayoshi M, Vos TJ, Williams J.
    Bioorg Med Chem Lett; 2010 Aug 15; 20(16):4795-9. PubMed ID: 20630752
    [Abstract] [Full Text] [Related]

  • 14. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC, Tarver JE, Carlsen M, Xu A, Healy JP, Heim-Riether A, Fu Q, Taylor JA, Augeri DJ, Shen M, Stouch TR, Swanson RV, Tari LW, Hunter M, Hoffman I, Keyes PE, Yu XC, Miranda M, Liu Q, Swaffield JC, David Kimball S, Nouraldeen A, Wilson AG, Foushee AM, Jhaver K, Finch R, Anderson S, Oravecz T, Carson KG.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6784-7. PubMed ID: 19836232
    [Abstract] [Full Text] [Related]

  • 15. Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.
    Gibson TS, Johnson B, Fanjul A, Halkowycz P, Dougan DR, Cole D, Swann S.
    Bioorg Med Chem Lett; 2017 Apr 15; 27(8):1709-1713. PubMed ID: 28291695
    [Abstract] [Full Text] [Related]

  • 16. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY, Choi JW, Yang J, Chae CH, Lee J, Jung H, Lee K, Ha JD, Kim HR, Cho SY.
    Bioorg Med Chem Lett; 2012 Apr 15; 22(8):2837-42. PubMed ID: 22450128
    [Abstract] [Full Text] [Related]

  • 17. Identification of novel ASK1 inhibitors using virtual screening.
    Okamoto M, Saito N, Kojima H, Okabe T, Takeda K, Ichijo H, Furuya T, Nagano T.
    Bioorg Med Chem; 2011 Jan 01; 19(1):486-9. PubMed ID: 21134755
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X, Chen W, Lin L, Ruiz CH, Cameron MD, Duckett DR, Kamenecka TM.
    Bioorg Med Chem Lett; 2011 Dec 01; 21(23):7072-5. PubMed ID: 22004719
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
    Zhang L, Bu T, Bao X, Liang T, Ge Y, Xu Y, Zhu Q.
    Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3395-3398. PubMed ID: 28633896
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.
    Marhadour S, Marchand P, Pagniez F, Bazin MA, Picot C, Lozach O, Ruchaud S, Antoine M, Meijer L, Rachidi N, Le Pape P.
    Eur J Med Chem; 2012 Dec 01; 58():543-56. PubMed ID: 23164660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.